Literature DB >> 23562131

Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI.

Lynda E Polgreen1, William Thomas2, Ellen Fung3, David Viskochil4, David A Stevenson4, Julia Steinberger5, Paul Orchard6, Chester B Whitley7, Kristine E Ensrud8.   

Abstract

Osteoporosis has been described in animal models of mucopolysaccharidosis (MPS). Whether clinically significant osteoporosis is common among children with MPS is unknown. Therefore, cross-sectional data from whole body (WB; excluding head) and lumbar spine (LS) bone mineral density (BMD) compared with sex-, chronologic age-, and ethnicity-matched healthy individuals (Zage), height-for-age (HAZ) Z-score (ZHAZ) and bone mineral content (BMC) measured by dual-energy X-ray absorptiometry (DXA) in 40 children with MPS were analyzed. A subset of these children (n=24) was matched 1:3 by age and sex to a group of healthy children (n=72) for comparison of BMC adjusted for Tanner stage, race, lean body mass, height, and bone area. Low BMD Z-score was defined as Z-score of -2 or less. In children with MPS, 15% had low WB Zage and 48% had low LS Zage; 0% and 6% had low WB ZHAZ and low LS ZHAZ, respectively. Adjusted WB BMC was lower in MPS participants (p=0.009). In conclusion, children with MPS had deficits in WB BMC after adjustments for stature and bone area. HAZ adjustment underestimated bone deficits (i.e., overestimated WB BMD Z-scores) in children with MPS likely owing to their abnormal bone shape. The influence of severe short stature and bone geometry on DXA measurements must be considered in children with MPS to avoid unnecessary exposure to antiresorptive treatments.
Copyright © 2014 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone mineral content; bone mineral density; mucopolysaccharidoses; osteoporosis; skeletal dysplasia

Mesh:

Year:  2013        PMID: 23562131      PMCID: PMC3872499          DOI: 10.1016/j.jocd.2013.03.004

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  23 in total

1.  The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.

Authors:  Roberto Lanes; Peter Gunczler; Sara Esaa; Jose R Weisinger
Journal:  Clin Endocrinol (Oxf)       Date:  2002-12       Impact factor: 3.478

2.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference.

Authors:  Sanford Baim; Mary B Leonard; Maria-Luisa Bianchi; Didier B Hans; Heidi J Kalkwarf; Craig B Langman; Frank Rauch
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

3.  Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.

Authors:  Wolfgang Högler; Julie Briody; Bin Moore; Pei Wen Lu; Christopher T Cowell
Journal:  Bone       Date:  2005-09-01       Impact factor: 4.398

4.  Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants.

Authors:  A Prentice; T J Parsons; T J Cole
Journal:  Am J Clin Nutr       Date:  1994-12       Impact factor: 7.045

5.  Radiological findings in patients with mucopolysaccharidosis I H/S (Hurler-Scheie syndrome).

Authors:  H Schmidt; K Ullrich; H J von Lengerke; M Kleine; J Brämswig
Journal:  Pediatr Radiol       Date:  1987

6.  Hurler syndrome with special reference to histologic abnormalities of the growth plate.

Authors:  C P Silveri; F S Kaplan; M D Fallon; E Bayever; C S August
Journal:  Clin Orthop Relat Res       Date:  1991-08       Impact factor: 4.176

7.  Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies.

Authors:  S Bhatia; N K Ramsay; D Weisdorf; H Griffiths; L L Robison
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

8.  Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children.

Authors:  Babette S Zemel; Mary B Leonard; Andrea Kelly; Joan M Lappe; Vicente Gilsanz; Sharon Oberfield; Soroosh Mahboubi; John A Shepherd; Thomas N Hangartner; Margaret M Frederick; Karen K Winer; Heidi J Kalkwarf
Journal:  J Clin Endocrinol Metab       Date:  2010-01-26       Impact factor: 5.958

9.  Modifiable risk factors associated with bone deficits in childhood cancer survivors.

Authors:  Lynda E Polgreen; Anna Petryk; Andrew C Dietz; Alan R Sinaiko; Wendy Leisenring; Pam Goodman; Lyn M Steffen; Joanna L Perkins; Donald R Dengel; K Scott Baker; Julia Steinberger
Journal:  BMC Pediatr       Date:  2012-03-28       Impact factor: 2.125

Review 10.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

View more
  19 in total

1.  Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.

Authors:  Sun H Peck; Philip J M O'Donnell; Jennifer L Kang; Neil R Malhotra; George R Dodge; Maurizio Pacifici; Eileen M Shore; Mark E Haskins; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2015-09-26       Impact factor: 4.797

2.  Abnormal epiphyseal development in a feline model of Sandhoff disease.

Authors:  Margaret A McNulty; Patricia B Prevatt; Elizabeth R Nussbaum; Ashley N Randle; Aime K Johnson; Judith A Hudson; Heather L Gray-Edwards; Miguel Sena-Esteves; Douglas R Martin; Cathy S Carlson
Journal:  J Orthop Res       Date:  2020-07-29       Impact factor: 3.494

3.  Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.

Authors:  Lynda E Polgreen; Richard K Vehe; Kyle Rudser; Alicia Kunin-Batson; Jeanine Jarnes Utz; Patricia Dickson; Elsa Shapiro; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-01-28       Impact factor: 4.797

4.  Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.

Authors:  Natalie E Taylor; Donald R Dengel; Troy C Lund; Kyle D Rudser; Paul J Orchard; Julia Steinberger; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

5.  Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome).

Authors:  Adrian Quartel; Christian J Hendriksz; Rossella Parini; Sue Graham; Ping Lin; Paul Harmatz
Journal:  JIMD Rep       Date:  2014-12-18

6.  Bone mineral density in patients with mucopolysaccharidosis type III.

Authors:  Banu Guzel Nur; Hakan Nur; Ercan Mihci
Journal:  J Bone Miner Metab       Date:  2016-05-18       Impact factor: 2.626

7.  Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

Authors:  David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

Review 8.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

9.  Bone mineral density in MPS IV A (Morquio syndrome type A).

Authors:  Heidi H Kecskemethy; Francyne Kubaski; H T Harcke; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2015-12-02       Impact factor: 4.797

Review 10.  Failures of Endochondral Ossification in the Mucopolysaccharidoses.

Authors:  Zhirui Jiang; Sharon Byers; Margret L Casal; Lachlan J Smith
Journal:  Curr Osteoporos Rep       Date:  2020-10-16       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.